ArticleMedical oncology (Northwood, London, England)2025
An investigative study on the impact of DLK1 and NCoR1 knockdown by siRNA transfection on endometrial cancer proliferation: unveiling notch interactions.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is the most common gynecological malignancy. Despite advances in treatment, many patients experience disease recurrence or metastasis. This study investigates the impact of siRNA-mediated gene knockdown of NCoR1 and DLK1 genes in the proliferation of endometrial cancer cell lines Ishikawa and AN3CA and normal HEK 293 cells. Cellular growth and survival before and after the treatment of predesigned siRNAs in the endometrial cancer cell lines were evidenced using fluorescent stains. The mRNA expression of BID, BAX, BCL2, Caspases 3, 8, and 9 GPR78, EGFR, VEGF, NCoR1, DLK1 and ARID1A was analyzed in the untreated HEK 293, Ishikawa, and AN3CA cell lines to substantiate the oncogenic property of Ishikawa and AN3CA cell lines. Then, to evidence the successful transfection of NCoR1 and DLK1 gene in endometrial cancer cells, the mRNA and protein expression of targeted genes before and after being transfected were also validated. As a result, the mRNA expression significantly increased in BID, BAX, BCL2, GPR78, EGFR and VEGF. On the other hand, Caspases 3, 8, and 9 were down-regulated in Ishikawa and AN3CA compared to the control cell line (HEK 293). The mRNA and protein expression of NCoR1 and DLK1 in siRNA-mediated transfection supported the reduced proliferation in endometrial cancer cells by interfering with certain pathways like Notch, MAPK, SWI/SNF, and NF-κB, which have crucial roles in the grade of receptor to the histone remodeling. With these findings, the study recommends exploring the possible role and interactions of NCoR1 and DLK1, signaling pathways that favor the progression of endometrial cancer.
Indexed as
Identifiers
40111664What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.